Imugene Ltd - Asset Resilience Ratio

Latest as of December 2025: 23.07%

Imugene Ltd (IMU) has an Asset Resilience Ratio of 23.07% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Imugene Ltd working capital to net assets to evaluate short-term liquidity relative to the company's equity base.

Liquid Assets

AU$15.61 Million
≈ $11.04 Million USD Cash + Short-term Investments

Total Assets

AU$67.67 Million
≈ $47.88 Million USD All company assets

Resilience Assessment

Good
Financial Resilience Level

Asset Resilience Ratio Trend (1995–2025)

This chart shows how Imugene Ltd's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see Imugene Ltd total assets.

Liquid Assets Composition Over Time

This chart breaks down Imugene Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore Imugene Ltd long-term investment allocation to see how much of total assets are deployed in long-term investments.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents AU$14.14 Million 20.89%
Short-term Investments AU$1.47 Million 2.18%
Total Liquid Assets AU$15.61 Million 23.07%

Asset Resilience Insights

  • Good Liquidity Position: Imugene Ltd maintains a healthy 23.07% of assets in liquid form.
  • This level provides good financial flexibility while maintaining productive asset deployment.
  • The company primarily holds liquidity in cash and equivalents rather than short-term investments.

Imugene Ltd Industry Peers by Asset Resilience Ratio

Compare Imugene Ltd's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Tubize-Fin
BR:TUB
Biotechnology 2.50%
Dianthus Therapeutics Inc.
NASDAQ:DNTH
Biotechnology 63.98%
Tango Therapeutics Inc
NASDAQ:TNGX
Biotechnology 62.24%
Damora Therapeutics, Inc.
NASDAQ:DMRA
Biotechnology 0.00%
Wecome Pharmaceutical Co Ltd
SHE:300878
Biotechnology 0.67%
Tectonic Therapeutic, Inc.
NASDAQ:TECX
Biotechnology 86.66%
Relmada Therapeutics Inc
NASDAQ:RLMD
Biotechnology 95.25%
MediWound Ltd
F:M8W
Biotechnology 56.04%

Annual Asset Resilience Ratio for Imugene Ltd (1995–2025)

The table below shows the annual Asset Resilience Ratio data for Imugene Ltd.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2025-06-30 2.49% AU$2.08 Million
≈ $1.47 Million
AU$83.59 Million
≈ $59.14 Million
-31.20pp
2024-06-30 33.69% AU$51.01 Million
≈ $36.09 Million
AU$151.40 Million
≈ $107.12 Million
+8.55pp
2023-06-30 25.14% AU$49.54 Million
≈ $35.05 Million
AU$197.06 Million
≈ $139.43 Million
+5.49pp
2022-06-30 19.65% AU$29.00 Million
≈ $20.52 Million
AU$147.61 Million
≈ $104.44 Million
-9.60pp
2021-06-30 29.25% AU$21.00 Million
≈ $14.86 Million
AU$71.81 Million
≈ $50.81 Million
-9.10pp
2020-06-30 38.34% AU$25.00 Million
≈ $17.69 Million
AU$65.20 Million
≈ $46.14 Million
-17.52pp
2019-06-30 55.87% AU$17.20 Million
≈ $12.17 Million
AU$30.78 Million
≈ $21.78 Million
+9.62pp
2018-06-30 46.25% AU$7.82 Million
≈ $5.53 Million
AU$16.91 Million
≈ $11.97 Million
+8.27pp
2017-06-30 37.97% AU$4.81 Million
≈ $3.41 Million
AU$12.68 Million
≈ $8.97 Million
--
2016-06-30 0.00% AU$0.00
≈ $0.00
AU$9.54 Million
≈ $6.75 Million
--
1996-06-30 4.18% AU$387.00K
≈ $273.83K
AU$9.25 Million
≈ $6.54 Million
+0.33pp
1995-06-30 3.86% AU$460.00K
≈ $325.48K
AU$11.93 Million
≈ $8.44 Million
--
pp = percentage points

About Imugene Ltd

AU:IMU Australia Biotechnology
Market Cap
$16.56 Million
AU$23.41 Million AUD
Market Cap Rank
#25788 Global
#1130 in Australia
Share Price
AU$0.05
Change (1 day)
+0.00%
52-Week Range
AU$0.05 - AU$0.45
All Time High
AU$0.61
About

Imugene Limited, a clinical-stage immuno-oncology company, develops a range of immunotherapies to activate the immune system of cancer patients to treat and eradicate tumours in Australia. Its lead products under development azer-cel, an allogeneic CAR T cell therapy in phase 1 clinical trial targeting relapsed/refractory non-hodgkin lymphoma and b-cell acute lymphoblastic leukemia; CF33 VAXINIA,… Read more